AG10-201: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of AG10 versus Placebo in ATTR-CM

**Background**
- Transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized form of heart failure for which there are no currently approved therapies.
- ATTR-CM occurs when transthyretin amyloid fibrils aggregate and deposit in the myocardium, resulting in an infiltrative, restrictive cardiomyopathy characterized by both right and left heart failure, initially with preserved ejection fraction.
- The disease results in progressive morbidity and high mortality due to the lack of modifying therapies and limited responsiveness to standard heart failure treatments.
- The initiating step of disease pathogenesis is the destabilization of the TTR tetrameric protein into its constituent monomers and subsequent misfolding into amyloid fibrils.
- AG10 is a highly selective and potent stabilizer of TTR that mimics the T119 rescue mutation and has the potential to become a disease-modifying treatment for patients with either mutant or wild-type ATTR cardiomyopathy.
- AG10 was found to be well-tolerated and demonstrated near-complete TTR stabilization in a recently completed Phase I study in healthy volunteers.

**PrimaryEndpoints**
- The primary endpoint is to characterize the safety and tolerability of AG10 administered to adult patients with symptomatic ATTR-CM over 28 days of dosing.

**SecondaryEndpoints**
- Pharmacokinetics: The PK measurements of AG10 and metabolites will be performed by a designated bioanalytical laboratory after the first dose and at steady state (Day 14, Day 28), and then at follow up.
- Pharmacodynamics: The PD measurements of AG10 will be assessed by proalbumin levels and established assays of TTR stabilization, including FPE assay and Western blot, to describe the PK-PD relationship of AG10 in adult patients with symptomatic ATTR-CM.

**Key InclusionCriteria**
1. A male or female ≥18 to ≤90 years of age.
2. Has an established diagnosis of ATTR-CM with either wild-type transthyretin or a variant transthyretin genotype (assayed by genotyping), with patients with concurrent monoclonal gammopathy of undetermined significance requiring a confirmatory test using mass spectrometry as defined by either positive endomycocardial biopsy or positive technetium phosphate scan.
3. Has a history of heart failure evidenced by at least one prior hospitalization for heart failure or clinical evidence of heart failure (without hospitalization) requiring medical management.
4. Has NYHA Class II-III symptoms.
5. For patients taking cardiovascular medical therapy, with the exception of diuretic dosing, must be on stable doses (defined as no greater than 50% dose adjustment and no categorical changes of medications) for at least 2 weeks prior to Screening.

**KeyExclusionCriteria**
1. Acute myocardial infarction, acute coronary syndrome or coronary revascularization within 90 days prior to Screening.
2. Experienced stroke within 90 days prior to Screening.
3. Has hemodynamic instability at Screening or Randomization that, in the judgment of the PI, would pose too great a risk for participation in the study.

**Key Exclusion Criteria cont.**
4. Is likely to undergo heart transplantation within the next year.
5. Has confirmed diagnosis of light-chain amyloidosis.
6. Has abnormalities in clinical laboratory tests or clinically significant ongoing medical condition at Screening or Randomization that, in the judgment of the PI, would pose too great a risk for participation in the study.
7. Current treatment with difusalin, tafamidis, green tea, doxycycline, TUDCA/ursodiol, Patiromer or Icrucenin within 14 days or 5 half-lives of the prior investigational agent (whichever is longer) prior to Screening.

**Study Design**
- Randomized, double-blind, placebo-controlled, multicenter
- Eligible patients will be randomized in a 1:1:1 ratio to AG10 400 mg twice daily, AG10 800 mg twice daily, or matching placebo for 28 days
- 49 subjects randomized (~16 subjects per arm)
- Following completion of double-blind treatment phase, subjects may continue in a separate open-label extension study
- Enrollment complete as of 18 June 2018: Screened 53, Randomized 49

**AG10FutureDevelopment**
A global phase 3 study in patients with symptomatic ATTR-CM is planned to begin in 2019. If you are interested in becoming a study site or interested in a list of sites in your area that will accepting patients for enrollment, please contact:
Eidos Therapeutics, Inc.
101 Montgomery St, STE 2550
San Francisco, California 94104
Phone: 415-887-1471 Email: info@eidostx.com

**References**